TEN Capital Network’s Post

#TENcapitalyear2023 Check out TEN Capital Network's top 5 videos of the year. Here's what our network was watching. Coming in at number 3: TEN Capital Presents Thromboembolic Diagnosis & Anticoagulant Management Watch Now: https://bit.ly/48wry6U

#TENcapitalyear2023 Check out TEN Capital Network's top 5 videos of the year. Here's what our network was watching. Coming in at number 3: TEN Capital Presents Thromboembolic Diagnosis & Anticoagulant Management Watch Now: https://bit.ly/48wry6U

Baxter bicarbonate-buffered solutions for CRRT, with various concentrations of electrolytes, help normalize electrolyte and acid-base disorders such as hyperkalemia, metabolic acidosis, hypocalcemia and hyperphosphatemia that can be associated with acute kidney injury (AKI).¹⁻⁴ Learn how Baxter’s portfolio of bicarbonate formulations enables individualized treatment to help meet a patient’s specific clinical needs as part of the hospital protocol. https://ow.ly/eS1850RTlnR AKI, acute kidney injury; CRRT, continuous renal replacement therapy For safe and proper use of the products mentioned herein, please refer to the Operator's Manual or Instructions for Use. References: 1. Claure-Del Granado R, et al. Blood Purif. 2012;34:186-193. 2. Biphozyl SmPC 2018-06. 3. Phoxilium 1.2 mmol/L phosphate SmPC 2023-03. 4. Hemosol B0 Package Leaflet 2018. #CRRT #AcuteTherapies #VitalOrganTherapies #AKI #CRRTSolutions #AcidBaseDisorders #PrisMax #MetabolicAcidosis

The phase III ELATIVE® trial offers new insights into treating primary biliary cholangitis (PBC). Learn how elafibranor, shows potential in patients who don’t respond to or tolerate ursodeoxycholic acid (UDCA). This video highlights key findings on its safety and efficacy. Watch the animated video for more details: https://hubs.ly/Q02SnmT-0 #PBC #LiverDisease #ELATIVETrial

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen III decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)

Explore a #ResearchHighlight on ATP citrate lyase (ACLY) as a pivotal factor in Metabolic (Dysfunction)-Associated Steatohepatitis (MASH), and discover its potential as a diagnostic and therapeutic target for MASH. https://bit.ly/4aWBojp #MetabolicResearch

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen III decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen Ill decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)